Login to Your Account



Pharma: Other News To Note


Thursday, August 1, 2013
• Life Technologies Corp., of Carlsbad, Calif., signed a long-term supply and exclusive licensing agreement with Novartis AG, of Basel, Switzerland, for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription